Mad2:
You are certainly welcome to address me by my first name since I have made it clear that I am nobody's doctor here and this is a speculative investment I have made.
1. Public information on Zinulose is available on the Zicam web site. If you want more, you will have to wait for data as the company releases as they see fit. Realize that peer-review journal articles often take up to a year for publication AFTER they have been received by the journal. How do I know? I have written several and will PM if you want, but they are completely irrelevant to this topic. Every time a nonsteroidal anti-inflammatory is released, do you insist on seeing a model of its molecular structure? They are not all prescription items, either.
2. The references on the web site are old but they are pertinent to the concepts about the common cold. Historical references are commonly cited thusly.
3.Papers by CB Hensley I found easily related to ion transport. I have NOT verified this is the same person and frankly find it irrelevant but will, unless you want to do so by CALLING GelTech yourself.
J Mol Cell Cardiol 1994 Apr;26(4):417-24
Amiodarone decreases Na,K-ATPase alpha 2 and beta 2 expression specifically in cardiac ventricle.
Hensley CB , Bersohn MM, Sarma JS, Singh BN, McDonough AA
Department of Physiology and Biophysics, University of Southern California School of Medicine, Los Angeles 90033.
Studies have suggested that chronic amiodarone treatment (a class III antiarrhythmic) may have effects on the myocardium that resemble those of hypothyroidism. Since hypothyroidism is associated with decreased expression of Na,K-ATPase alpha 1, alpha 2 and beta 1 subunits in heart and alpha 2 subunit in skeletal muscle, we aimed to test the hypothesis that chronic in vivo administration of amiodarone would result in changes in the expression of Na,K-ATPase isoforms that resembled those seen in hypothyroid rat. Rats were treated with 40 micrograms/g body weight amiodarone for 3 and 6 weeks. Na,K-ATPase alpha 1, alpha 2, beta 1 mRNA and protein levels and beta 2 mRNA were measured in cardiac ventricle and skeletal muscle. After 3 weeks of amiodarone cardiac alpha 1, alpha 2 and beta 1 protein levels were decreased to 0.65, 0.42, and 0.54 of control, respectively. After 6 weeks of treatment, cardiac alpha 1 and beta 1 levels returned to control and alpha 2 remained depressed. At the mRNA level alpha 2 and beta 2 decreased to 0.6-fold of control after 6 weeks treatment. There was no effect of amiodarone on skeletal muscle Na,K-ATPase expression at either time point. We conclude that the effects of amiodarone on myocardial Na,K-ATPase expression are similar to those of hypothyroidism after 3 weeks of amiodarone treatment, but by 6 weeks the similarities are limited to the decrease in alpha 2 and beta 2 expression.
Am J Physiol 1992 Feb;262(2 Pt 1):C484-92
Thyroid hormone induction of rat myocardial Na(+)-K(+)-ATPase: alpha 1-, alpha 2-, and beta 1-mRNA and -protein levels at steady state.
Hensley CB, Azuma KK, Tang MJ, McDonough AA
Department of Physiology and Biophysics, University of Southern California School of Medicine, Los Angeles 90033.
In this study, we measured the time courses of change in Na(+)-K(+)-ATPase alpha 1-, alpha 2-, and beta 1-subunit mRNA and protein abundance in cardiac myocytes isolated from euthyroid, hypothyroid, and hyperthyroid (hypothyroids injected daily with 1 microgram T3/g body wt) rats. In hypothyroids, alpha 1-, alpha 2-, and beta 1-protein levels were decreased to 0.55, 0.42, and 0.57 of euthyroids, predicting the decrease in Na(+)-K(+)-ATPase activity to 0.53 of control. There was no change in these subunits' mRNA levels, indicating that the decreases in protein levels were not due to decreased subunit transcription rates. In hyperthyroids, the alpha 1-mRNA increased to a steady state of threefold over hypothyroid by 1 day of T3 treatment, and the alpha 1-protein levels increased to twofold over hypothyroid by 4 days of T3. alpha 2-mRNA increased to 5-fold over hypothyroid by 2 days, whereas the alpha 2-protein levels increased to 14-fold above hypothyroid by 4 days of T3. Beta 1-mRNA increased to 12-fold above hypothyroid by 1 day of T3 treatment, whereas beta 1-protein increased to only 2.5-fold over hypothyroid by 4 days of T3. The discoordinate changes in alpha 2- and beta 1-mRNA vs. protein can be reconciled with the hypothesis that beta 1 is rate limiting for assembly in eu- and hypothyroids, and favors assembly with alpha 1, while excess unassembled alpha 2 is degraded. In the hyperthyroids we predict beta 1 is not rate limiting and there is increased alpha 2 beta 1-assembly. We calculate that T3 decreases the alpha 1-to-alpha 2 ratio from 24:1 in hypothyroid to 3.4:1 in hyperthyroid cardiomyocytes.
********
My point is only that EVERY Ph.D. has scientific papers published, so your conjecture ("fields indicating to me they aren't researchers")
is incorrect and irrelevant in any case. Do you doubt the existence of the product? If somebody's mother invented whiteout and she wasn't a researcher, does that matter?
4. "Gel Tech is listed to be a wholesaler of pharmacology materials by ABI" . This statement is irrelevant, in my opinion. Do you doubt the existence of the product? I have some. My partner's sister just took it for her cold and it went away in less than 24 hours. Yes this is an anecdote and not a double-blind study. But she will be a repeat customer. Are you saying GelTech can't legally make this material? Just what is the point? All your points on that topic are irrelevant, in my opinion & I am not trying to insult you personally, just expressing my opinion.
5.Thank you for asking pertinent questions about the qualifications of the physicians listed on the Zicam site. Post the same questions to the company and tell me what your responses are. Or call the company. The company has submitted papers to peer-reviewed journals but usually one cannot release the name until they are published. Most journals will not allow you to excerpt papers until they are published; otherwise the particular journal is not the first place the material is published and journals not only do not like that, but they require you to sign statements saying you will not publish your same data anywhere else.
Thank you for keeping this discourse above the level of personal attack. You may short away as you wish. This is a speculative investment. I have made some before and am not uncomfortable with that. I do understand more about this than I do about the differences between Netopia's products, Fore's products, Lucent's products, and Xylan's products. So maybe I am stupid for investing in (or in & out) of some of these. I know nothing about middleware but have more than doubled my money on HDIE and tripled my money on VETX. And I do not feel stupid or incompletely informed about them. Turnaround plays exist in all fields. This, to me, as an investor with a little scientific knowledge, seems to me to have a most excellent upside potential. And I am willing to take the associated risks.
Regards,
Howard |
